RxDoctor Payments Data

Hossein Alimadadian, MD

Cardiovascular Disease · Orange, CANPI 1285664029

Payments from drug & device makers

$5,092in general payments, 2019–2025

Across 278 payments — averaging $18.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$813
  • Johnson & Johnson$447
  • Boehringer Ingelheim$438
  • Amgen$389
  • Pfizer$335
  • AstraZeneca$326
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$4,90196%
  • Education$1924%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,092 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$217,118
Medicare patients
367
Services billed
1,721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan104$154,035
XareltoRivaroxaban123$133,438
EliquisApixaban71$99,327
Repatha SureclickEvolocumab53$32,569
MultaqDronedarone Hcl30$28,454
JardianceEmpagliflozin23$26,222
VascepaIcosapent Ethyl45$22,522
Praluent PenAlirocumab22$10,534
Icosapent Ethyl34$7,999
Rosuvastatin Calcium195$3,936
Nebivolol Hcl36$2,636
Ezetimibe77$1,876
Ezetimibe-SimvastatinEzetimibe/Simvastatin23$1,662
Losartan Potassium143$1,542
Metoprolol Succinate56$1,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$813$154,035104 claims
Johnson & JohnsonXarelto$447$133,438123 claims
PfizerEliquis$335$99,32771 claims
Sanofi-aventis U.S. LLCMultaq$244$28,45430 claims
Boehringer IngelheimJardiance$438$26,22223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →